Jump to content
This site uses cookies. Continued use is acceptance of our Terms of Use and Privacy Policy. More Info... ×
  • Welcome to Celiac.com!

    You have found your celiac tribe! Join us and ask questions in our forum, share your story, and connect with others.




  • Celiac.com Sponsor (A1):



    Celiac.com Sponsor (A1-M):


  • Get Celiac.com Updates:
    Where Your Contribution Counts!
    eNewsletter
    Support Us!
  • Record is Archived

    This article is now archived and is closed to further replies.

    Jefferson Adams
    Jefferson Adams

    Mayo Clinic Says New Celiac Drug Reduces GI and Non-GI Symptoms

    Reviewed and edited by a celiac disease expert.
    Mayo Clinic Says New Celiac Drug Reduces GI and Non-GI Symptoms - Photo: CC--michael hicks
    Caption: Photo: CC--michael hicks

    Celiac.com 07/28/2014 - One angle being tried by researchers to treat celiac disease involves oral peptides. These are orally administered drugs that would prevent an adverse gluten reaction in people with celiac disease who are following a gluten-free diet.

    Photo: CC--michael_hicksThe drugs are intended to prevent adverse reactions from minor gluten contamination or exposure.

    Celiac.com Sponsor (A12):
    In a recent update from the Mayo clinic, Joseph Murray, MD, confirms that larazotide acetate, a first-in-class oral peptide, has ”met the study's primary end point of a reduction in GI symptoms.” Dr. Murray presented the results from the study as a late-breaking abstract at Digestive Disease Week 2014.

    In a celiac disease reaction, the epithelial tight junctions that control paracellular permeability are compromised, and gut permeability increases. This is partly due to an inflammatory immune response to the entrance of gluten peptides into the intestinal lamina propria through these tight junctions.

    Larazotide acetate prevents tight-junction opening and reduces gluten uptake, inhibiting gluten- and cytokine-induced intestinal permeability and inflammation in vivo.

    This randomized, parallel, double-blind, placebo-controlled, multicenter trial was conducted at 74 sites in North America. The aim was to evaluate the effect of larazotide acetate on GI signs and symptoms in patients with celiac disease.

    Source:

    • Open Original Shared Link


    User Feedback

    Recommended Comments

    Guest dappy

    Posted

    A waste of research time and money. We need a better solution than this band aid. Put the money to a more specific solution of counteracting the reaction to gluten in the intestine.

    Link to comment
    Share on other sites
    Guest Roberta

    Posted

    Does anyone know when larazotide acetate will be available for consumer use?

    Link to comment
    Share on other sites
    Guest Jefferson

    Posted

    A waste of research time and money. We need a better solution than this band aid. Put the money to a more specific solution of counteracting the reaction to gluten in the intestine.

    As I read it, this new drug does just that. What is your compliant, exactly?

    Link to comment
    Share on other sites
    Guest Jefferson

    Posted

    Does anyone know when larazotide acetate will be available for consumer use?

    It's currently in early phase trials. If all goes well the company will apply for FDA approval. Still no time frame beyond early trial information. Stay tuned!

    Link to comment
    Share on other sites
    Guest Anne

    I would love to have something that would help take the worry out of cross contamination when eating out but I am hoping that the enzymes that are in clinical trials will do this. I worry about long term problems when we try to modify a normal response. Zonulin causes leaky gut in everyone - in those with celiac disease the junctions are opened for a longer time. I heard Dr. Fasano say that Zonulin is there for a purpose and we don't fully understand it. Is it really safe to inhibit to inhibit this?

    Link to comment
    Share on other sites
    Guest Tricia M. Hutto, Pharmacist

    Posted

    As I read it, this new drug does just that. What is your compliant, exactly?

    Larazotide does not guard against the long term effect of gluten ingestion for celiac patients. It is designed only to reduce the symptoms that patients experience when they do ingest gluten. This drug is by no means the answer for celiac patients to be able to stop the gluten free diet and not suffer the negative long term effect gluten ingestion will have on the gut.

    Link to comment
    Share on other sites


    Guest
    This is now closed for further comments

  • Get Celiac.com Updates:
    Help Celiac.com:
    Donate
  • About Me

    Jefferson Adams

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University. His articles, essays, poems, stories and book reviews have appeared in numerous magazines, journals, and websites, including North American Project, Antioch Review, Caliban, Mississippi Review, Slate, and more. He is the author of more than 2,500 articles on celiac disease. His university coursework includes studies in science, scientific methodology, biology, anatomy, physiology, medicine, logic, and advanced research. He previously devised health and medical content for Colgate, Dove, Pfizer, Sharecare, Walgreens, and more. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of numerous books, including "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

    >VIEW ALL ARTICLES BY JEFFERSON ADAMS

     


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-M):




  • Related Articles

    Scott Adams
    Am J Gastroenterol. 2004 May;99(5):894-904 Celiac.com 06/08/2004 – To determine what triggers celiac disease, researchers recently used an electron microscope to look at the jejunal biopsies of several groups of children: A group with untreated celiac disease, one with treated celiac disease, another with challenged celiac disease, and a healthy control group. The researchers discovered rod-shaped bacteria attached to the small intestinal epithelium in both the treated and untreated celiac-disease groups, but not in the healthy control group.
    The researchers conclude: "Unique carbohydrate structures of the glycocalyx/mucous layer are likely discriminating features of celiac disease patients. These glycosylation differences could facilitate bacterial adhesion. Ectopic production o...


    Jefferson Adams
    Celiac.com 04/24/2009 - Currently, one of the more promising areas of celiac disease research looks to be in peptide-based therapies. One of the keys to creating an effective peptide-based therapy for celiac disease lies in identifying the gluten peptides that trigger intestinal T cell responses when people with celiac disease consume wheat, rye, or barley.
    A team of Italian researchers recently set out to do just that. The team was made up of A. Camarca, R.P. Anderson, G. Mamone, O. Fierro , A. Facchiano, S. Costantini, D. Zanzi, J. Sidney, S. Auricchio, A. Sette, R. Troncone, and C. Gianfrani. Their efforts were supported by the Institute of Food Sciences-National Research Council, Avellino, Italy. Their research carries strong implications for a Open Original Shared Link.
    Presently...


    Jefferson Adams
    Celiac.com 08/01/2011 - Over the last two decades, there has been a marked increase in the prevalence of celiac disease, especially the sub-clinical celiac disease forms and non-celiac gluten sensitivity. Most people with celiac disease now present atypical or non-classical symptoms.
    However, even with improved evaluation methods, clinicians may often face variable histological and clinical presentations of celiac disease, and they may be confused by diagnostic models in the current guidelines.
    A team of researchers recently set out to reassess sub-clinical celiac disease and gluten sensitivity. The study team included Mohammad Rostami Nejad, Sabine Hogg- Kollars, Sauid Ishaq, Kamran Rostami
    They are affiliated variously with the Research Institute for Gastroenterology and...


    Jefferson Adams
    Celiac.com 12/12/2012 - In duodenal biopsy samples from people with active celiac disease, the transferrin receptor, CD71, is up-regulated, and promotes retro-transport of secretory immunoglobulin A (SIgA)-gliadin complexes.
    To better understand how interactions between SIgA and CD71 promote transepithelial transport of gliadin peptides, a team of researchers set out to determine if interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides.
    The research team included C. Lebreton, S. Ménard, J. Abed, I.C. Moura, R. Coppo, C. Dugave, R.C. Monteiro, A. Fricot, M.G. Traore, M. Griffin, C. Cellier, G. Malamut, N. Cerf-Bensussan, and M. Heyman. They are affiliated with the Mixed Research Unit 989...


  • Recent Activity

    1. - Julie Riordan replied to Julie Riordan's topic in Traveling with Celiac Disease
      3

      Any ideas for travelling

    2. - trents replied to SuzanneL's topic in Celiac Disease Pre-Diagnosis, Testing & Symptoms
      1

      Weak Positive Test

    3. - SuzanneL posted a topic in Celiac Disease Pre-Diagnosis, Testing & Symptoms
      1

      Weak Positive Test

    4. - Scott Adams replied to Braver101's topic in Coping with Celiac Disease
      2

      Constant sweating with celiac disease

    5. - Scott Adams replied to Julie Riordan's topic in Traveling with Celiac Disease
      3

      Any ideas for travelling


  • Celiac.com Sponsor (A19):



  • Member Statistics

    • Total Members
      120,495
    • Most Online (within 30 mins)
      7,748

    Zofosho
    Newest Member
    Zofosho
    Joined

  • Celiac.com Sponsor (A20):


  • Forum Statistics

    • Total Topics
      120.2k
    • Total Posts
      1m

  • Celiac.com Sponsor (A22):




  • Who's Online (See full list)

    • There are no registered users currently online

  • Celiac.com Sponsor (A21):



  • Popular Now

    • JustGemi
    • Linedancegal
    • Hannah24
      9
    • jessiemariecar
    • Rhonda H
  • Popular Articles

    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
  • Upcoming Events

×
×
  • Create New...